Vimarsana
Biggest News Aggregation in the World

Anna Sussman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anna Sussman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anna Sussman Today - Breaking & Trending Today

On The Foreign Buyers Tax, And Attack Ads - Vimarsana News

On The Foreign Buyers Tax, And Attack Ads

It has now been six days since National unveiled its tax plan – eons ago in the 24/7 news cycle – but the credibility problem with it just won’t go away. Tax cuts are never a free lunch. The revenue for them has to come from somewhere. It ...

The Global Sperm Count Decline Has Created Big Business - Vimarsana News

The Global Sperm Count Decline Has Created Big Business

The worldwide decline in male fertility has created tantalizing business opportunities and disorienting politics. Legacy, the sperm-test-kit start-up company, offers semen analysis and sperm freezing.

Source: nymag.com
The Sunday Story: When Parents Overshare Online : Up First : NPR - Vimarsana News

The Sunday Story: When Parents Overshare Online : Up First : NPR

"It's this version of me that my mom's publicized and made very permanent."Lou grew up as a social media baby. Their mom had a public blog where she shared details about her life as a mother. But she also shared details about her kids, including Lou. Now, Lou remembers the blog as a fixture of their childhood, but not in a good way. Throughout their teen years and into adulthood, strange adults would reach out to Lou online, asking personal and often inappropriate questions. Classmates would use content from the blog to embarrass them. Lou is part of a generation of social ...

Source: npr.org
Clovis Oncology, Inc.: Clovis Oncology's Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups - Vimarsana News

Clovis Oncology, Inc.: Clovis Oncology's Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented in a Mini Oral session at the ESMO Congress 2022 Results reinforce potential

List: Biotech Companies at Highest Risk of Bankruptcy - Vimarsana News

List: Biotech Companies at Highest Risk of Bankruptcy

Biotech stocks have lost nearly half their value this year, putting cash-starved or debt-laden firms at risk.